A refined, rapid and reproducible high resolution melt (HRM)-based method suitable for quantification of global LINE-1 repetitive element methylation

被引：38

作者：

Tse M.Y. ^{[1
]}

Ashbury J.E. ^{[2
]}

Zwingerman N. ^{[2
]}

King W.D. ^{[2
]}

Taylor S.A.M. ^{[3
,4
]}

Pang S.C. ^{[1
]}

机构：

[1] Department of Anatomy and Cell Biology, Queen's University, Kingston, ON

[2] Department of Community Health and Epidemiology, Queen's University, Kingston, ON

[3] Department of Laboratory Medicine, Saint John Regional Hospital, Horizon Health Network, Halifax, NS

[4] Department of Pathology, Dalhousie University, Halifax, NS

来源：

BMC Research Notes | / 4卷 / 1期

基金：

加拿大创新基金会;

关键词：

Methylation Level; Single Nucleotide Polymorphism; High Resolution Melting; High Resolution Melting Analysis; Percent Methylation;

D O I：

10.1186/1756-0500-4-565

中图分类号：

学科分类号：

摘要：

Background: The methylation of DNA is recognized as a key mechanism in the regulation of genomic stability and evidence for its role in the development of cancer is accumulating. LINE-1 methylation status represents a surrogate measure of genome-wide methylation. Findings. Using high resolution melt (HRM) curve analysis technology, we have established an in-tube assay that is linear (r > 0.9986) with a high amplification efficiency (90-105%), capable of discriminating between partcipant samples with small differences in methylation, and suitable for quantifying a wide range of LINE-1 methylation levels (0-100%) - including the biologically relevant range of 50-90% expected in human DNA. We have optimized this procedure to perform using 2 g of starting DNA and 2 ng of bisulfite-converted DNA for each PCR reaction. Intra- and inter-assay coefficients of variation were 1.44% and 0.49%, respectively, supporting the high reproducibility and precision of this approach. Conclusions: In summary, this is a completely linear, quantitative HRM PCR method developed for the measurement of LINE-1 methylation. This cost-efficient, refined and reproducible assay can be performed using minimal amounts of starting DNA. These features make our assay suitable for high throughput analysis of multiple samples from large population-based studies. © 2011 Tse et al; licensee BioMed Central Ltd.

引用

共 55 条

[1]

Tost J., Epigenetics, (2008)

[2]

Garber K., Breaking the silence: The rise of epigenetic therapy, Journal of the National Cancer Institute, 94, 12, pp. 874-875, (2002)

[3]

Moore L.E., Huang W.-Y., Chung J., Hayes R.B., Epidemiologic considerations to assess altered DNA methylation from environmental exposures in cancer, Annals of the New York Academy of Sciences, 983, pp. 181-196, (2003)

[4]

Zhu X., Zheng L., Asa S.L., Ezzat S., Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer, Am J Pathol, 177, pp. 2860-2869, (2010)

[5]

Esteller M., Fraga M.F., Paz M.F., Campo E., Colomer D., Novo F.J., Cancer epigenetics and methylation, Science, 297, pp. 1807-1808, (2002)

[6]

Herceg Z., Epigenetics and cancer: Towards an evaluation of the impact of environmental and dietary factors, Mutagenesis, 22, 2, pp. 91-103, (2007)

[7]

Laird P.W., The power and the promise of DNA methylation markers, Nature Reviews Cancer, 3, 4, pp. 253-266, (2003)

[8]

Chen K., Wang G., Peng L., Liu S., Fu X., Zhou Y., CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease, Int J Cancer, 128, pp. 266-273, (2011)

[9]

Perry A.S., Watson R.W., Lawler M., Hollywood D., The epigenome as a therapeutic target in prostate cancer, Nat Rev Urol, 7, pp. 668-680, (2010)

[10]

Esteller M., Epigenetic changes in cancer, F1000 Biol Rep, 3, (2011)

← 1 2 3 4 5 6 →